ES2000278A6 - Procedimiento para preparar una proteina de fusion y para preparar una proteina eucariotica. - Google Patents

Procedimiento para preparar una proteina de fusion y para preparar una proteina eucariotica.

Info

Publication number
ES2000278A6
ES2000278A6 ES8600544A ES8600544A ES2000278A6 ES 2000278 A6 ES2000278 A6 ES 2000278A6 ES 8600544 A ES8600544 A ES 8600544A ES 8600544 A ES8600544 A ES 8600544A ES 2000278 A6 ES2000278 A6 ES 2000278A6
Authority
ES
Spain
Prior art keywords
sequence
amino acids
preparing
fusion protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8600544A
Other languages
English (en)
Inventor
Paul Habermann
Siegfried Stengelin
Friedrich Wengenmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of ES2000278A6 publication Critical patent/ES2000278A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

UN SEGMENTO DE APROXIMADAMENTE 70 AMINOACIDOS A PARTIR DE LA PROTEINA D DEL OPERON TRP DE E. COLI ES APROPIADO PARA LA CONSTRUCCION POR TECNOLOGIA GENETICA DE PROTEINAS DE FUSION, QUE PUEDEN CONTENER DELANTE DEL N-TERMINAL DE LA PROTEINA DESEADA UNA CORTA SECUENCIA DE AMINOACIDOS A BASE DE AMINOACIDOS CODIFICABLES GENETICAMENTE, LA CUAL ES PREFERIBLEMENTE LYS-ALA O CONTIENE N-TERMINALMENTE LYS-ALA.
ES8600544A 1985-07-27 1986-07-24 Procedimiento para preparar una proteina de fusion y para preparar una proteina eucariotica. Expired ES2000278A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853526995 DE3526995A1 (de) 1985-07-27 1985-07-27 Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung

Publications (1)

Publication Number Publication Date
ES2000278A6 true ES2000278A6 (es) 1988-02-01

Family

ID=6276985

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8600544A Expired ES2000278A6 (es) 1985-07-27 1986-07-24 Procedimiento para preparar una proteina de fusion y para preparar una proteina eucariotica.

Country Status (18)

Country Link
EP (1) EP0211299B1 (es)
JP (1) JPH07113040B2 (es)
KR (1) KR950000299B1 (es)
AT (1) ATE50596T1 (es)
AU (1) AU595221B2 (es)
CA (1) CA1336329C (es)
DE (2) DE3526995A1 (es)
DK (1) DK172618B1 (es)
ES (1) ES2000278A6 (es)
FI (1) FI86887C (es)
GR (1) GR861957B (es)
HU (1) HU197356B (es)
IE (1) IE59127B1 (es)
IL (1) IL79522A (es)
NO (1) NO175640C (es)
NZ (1) NZ216967A (es)
PT (1) PT83065B (es)
ZA (1) ZA865556B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738541A1 (de) * 1987-11-13 1989-05-24 Hoechst Ag Verfahren zur isolierung und reinigung von hirudin
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
EP0237338B1 (en) * 1986-03-12 1992-09-23 IMCERA Group Inc. Hybrid expression vectors, their construction and uses
EP0371041A1 (en) * 1987-06-24 1990-06-06 Novo Nordisk A/S A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
US5179196A (en) * 1989-05-04 1993-01-12 Sri International Purification of proteins employing ctap-iii fusions
US5227293A (en) * 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
US5358857A (en) * 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
IL95495A (en) * 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE3942580A1 (de) * 1989-12-22 1991-06-27 Basf Ag Verfahren zur herstellung von hirudin
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
JP5368450B2 (ja) 2007-09-21 2013-12-18 カディラ・ヘルスケア・リミテッド ペプチドの高発現に適した融合タンパク質システム
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA802992B (en) * 1979-06-01 1981-10-28 Univ California Human pre-growth hormone
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
EP0217916A4 (en) * 1985-03-18 1989-02-23 Gene Labs Inc CASSETTE VECTOR WITH HYBRID GEN.
GB8507666D0 (en) * 1985-03-25 1985-05-01 Wellcome Found Epidermal growth factor production
ATE109512T1 (de) * 1985-04-08 1994-08-15 Genetic Systems Corp Expression und diagnose mit gag-kodierten peptiden, die mit antikörpern gegen lav immunologisch reaktiv sind.

Also Published As

Publication number Publication date
NO175640C (no) 1994-11-09
DE3669175D1 (de) 1990-04-05
PT83065A (de) 1986-08-01
GR861957B (en) 1986-11-25
FI86887C (fi) 1992-10-26
KR870001312A (ko) 1987-03-13
NO863000L (no) 1987-01-28
ATE50596T1 (de) 1990-03-15
NZ216967A (en) 1988-08-30
FI863041A0 (fi) 1986-07-24
IL79522A0 (en) 1986-10-31
JPH07113040B2 (ja) 1995-12-06
DK172618B1 (da) 1999-03-01
DK355486D0 (da) 1986-07-25
JPS6229600A (ja) 1987-02-07
NO863000D0 (no) 1986-07-25
PT83065B (pt) 1989-02-28
NO175640B (es) 1994-08-01
AU6056586A (en) 1987-01-29
IE59127B1 (en) 1994-01-12
ZA865556B (en) 1987-03-25
FI86887B (fi) 1992-07-15
HU197356B (en) 1989-03-28
DE3526995A1 (de) 1987-02-05
FI863041L (fi) 1987-01-28
DK355486A (da) 1987-01-28
EP0211299A3 (en) 1988-06-01
IL79522A (en) 1991-08-16
KR950000299B1 (ko) 1995-01-13
AU595221B2 (en) 1990-03-29
CA1336329C (en) 1995-07-18
HUT43629A (en) 1987-11-30
IE861977L (en) 1987-01-27
EP0211299A2 (de) 1987-02-25
EP0211299B1 (de) 1990-02-28

Similar Documents

Publication Publication Date Title
AU595221B2 (en) Fusion proteins, a process for their preparation and their use
EP0722461A4 (en) EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
DZ467A1 (fr) Interferon immunitaire urbain.
FI880017A0 (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
ATE426024T1 (de) C-c chemokin rezeptor 3: ckr-3 oder eos-l2
DE68922917D1 (de) KEX2-Endoprotease und Verfahren zu ihrer Herstellung.
DE3584579D1 (de) Herstellung von polypeptiden mit human-gammainterferon-aktivitaet.
BG60255B2 (bg) Метод за получаване на пептиди
ES2007425A6 (es) Un metodo para la produccion de una proteina con actividad inhibidora del crecimiento de tumores.
ATE89317T1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
BG50281A3 (bg) Метод за получаване на рекомбинантн днк експресионен вектор
DK0652903T3 (da) Nyt humant rekombinant gammainterferon
NO911557D0 (no) Fremgangsmaate for fremstilling av fremmedproteiner i streptomyceter.
SE8601940D0 (sv) Preparation of fused proteins, antibodies and processes therefor
EP0330700A4 (en) Human prourokinase-like polypeptide.
ATE46188T1 (de) Positionsspezifische proteolyse mittels renin.
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
YU48126B (sh) Postupak za pripremanje proteina plasmodium falciparum-a

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20060725